These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33450815)

  • 1. Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Wang C; Zhang Z; Chong W; Luo R; Myers RE; Gu J; Lin J; Wei Q; Li B; Rebbeck TR; Lu-Yao G; Kelly WK; Yang H
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33450815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
    Chong W; Zhang Z; Luo R; Gu J; Lin J; Wei Q; Li B; Myers R; Lu-Yao G; Kelly WK; Wang C; Yang H
    BMC Cancer; 2021 Jun; 21(1):655. PubMed ID: 34078304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
    Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
    Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    Goldkorn A; Tangen C; Plets M; Bsteh D; Xu T; Pinski JK; Ingles S; Triche TJ; MacVicar GR; Vaena DA; Crispino AW; McConkey DJ; Lara PN; Hussain MHA; Quinn DI; Dorff TB; Lerner SP; Thompson I; Agarwal N
    JAMA Netw Open; 2024 Oct; 7(10):e2437871. PubMed ID: 39374015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients.
    Gu T; Li J; Chen T; Zhu Q; Ding J
    Int Urol Nephrol; 2023 Apr; 55(4):883-892. PubMed ID: 36709467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
    BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
    Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study.
    Koinis F; Zafeiriou Z; Messaritakis I; Katsaounis P; Koumarianou A; Kontopodis E; Chantzara E; Aidarinis C; Lazarou A; Christodoulopoulos G; Emmanouilides C; Hatzidaki D; Kallergi G; Georgoulias V; Kotsakis A
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.
    Gupta S; Halabi S; Yang Q; Roy A; Tubbs A; Gore Y; George DJ; Nanus DM; Antonarakis ES; Danila DC; Szmulewitz RZ; Wenstrup R; Armstrong AJ
    Clin Cancer Res; 2023 May; 29(10):1929-1937. PubMed ID: 36897758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy.
    Yang G; Xie J; Zhang S; Gu W; Yuan J; Wang R; Guo C; Ye L; Peng B; Yao X; Yang B
    Front Oncol; 2021; 11():812549. PubMed ID: 35127528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
    Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
    Zhang Z; Luo R; Kelly WK; Chen J; Donahue S; Ip K; Handley NR; Tester WJ; Tsang ML; Kim FJ; Myers R; Lu-Yao G; Gu J; Lin J; Li B; Wang C; Yang H
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):339-347. PubMed ID: 38057610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
    Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
    Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of a Real-World Cohort of Metastatic Breast Cancer Patients Shows Circulating Tumor Cell Clusters (CTC-clusters) as Predictors of Patient Outcomes.
    Costa C; Muinelo-Romay L; Cebey-López V; Pereira-Veiga T; Martínez-Pena I; Abreu M; Abalo A; Lago-Lestón RM; Abuín C; Palacios P; Cueva J; Piñeiro R; López-López R
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
    Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
    J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
    Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S
    Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.